Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Civica Rx Gets $55m Investment

Strikes Deal With Blue Cross Blue Shield Insurance Group

Executive Summary

Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.

You may also be interested in...



Sandoz And Civica Rx Strike Five-Year Deal

Sandoz and Civica Rx have entered into a long-term collaboration to help mitigate medicine shortages in US hospitals, where Sandoz will supply six critical injectables and Civica will ensure reliable supply of these medicines to patients.

Civica Rx Partners With Kaiser Permanente

Civica Rx and Kaiser, two non-profit organizations, have announced a partnership to ensure the uninterrupted supply of essential generics to health providers across US during the coronavirus pandemic.

Civica Interested In Retired Or Withdrawn ANDAs

As a part of its strategy to develop its own ANDAs for essential medications, Civica has expressed interest in taking over existing ANDAs that are being retired or withdrawn by other generics manufacturers.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149551

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel